


Phage*Tech*

New Classes of Antibiotics From Phage Genomics

From Phage Genomics To Antimicrobial Drug Discovery

PhageTech Drug Discovery Tools



The PhageTech Advantage in Antimicrobial Discovery


- Proprietary screening assays and tools developed at PhageTech exploit the interaction between phage-encoded antimicrobial proteins and their cognate targets in bacteria
- PhageTech aims to identify small molecule drug candidates that inhibit the same targets as the phage inhibitory ORFs do

Key advantages of the PhageTech approach:


- **speed of analysis** of small phage genomes
- **inherent validation** of the bacterial target by evolution
- rapid access to **diversified targets**
- requisite **positive control** for target screening assays

Genome Map for *S. aureus* Phage 77


Bacteriophage 77, 41708 nucleotides
100 genes
Minimal gene size: 33 amino acids



High Throughput Screening for Phage Inhibitory ORFs



Identification of inhibitory 77ORF04



Without inducer

With inducer

Induction of 77ORF104 is Bacteristatic for *S. aureus*


Transform *S. aureus*
with inhibitory ORF



Grow clones
+/- inducer



Determine phenotype
of growth inhibition



Summary of PhageTech's Genomics and Functional Genomics Programs

Bacterial pathogen	Phages collected	Genomes sequenced	ORFs screened	Inhibitor families
<i>S. aureus</i>	150	27	964	31
<i>S. pneumoniae</i>	50	8	264	5
<i>P. aeruginosa</i>	70	11	210?	9?
Total	329	47	1438?	45?

Target Identification and Validation

ORF Affinity Approach to Target ID

Affinity chromatography of bacterial lysate over immobilized inhibitory ORF



Tryptic peptide mapping, mass spectrometry of eluted proteins



Target identification



Target validation

- Confirm ORF-Target interaction
- Confirm target essentiality
- Determine target function

Identification of Dnal as a *S. aureus* Target of 77ORF104

Lysate alone

GST + Lysate

77ORF104 + Lysate

77ORF104 - lysate



← R1 specific band

Identification of the cellular target of 77ORF104 by affinity chromatography:

Purified 77ORF104 and GST proteins were crosslinked to affigel and then incubated with *S. aureus* lysate.

Specific bands were eluted by 1% SDS and proteins were resolved on a 12% SDS gel. Specific band was excised from the gel and subjected to mass spectrophotometry for identification.

Validation of Bacterial Targets from the Proteomics Platform

- Direct interactions between inhibitory phage ORFs and their cognate bacterial targets were confirmed by:
 - Yeast two-hybrid analysis
 - Far western (protein blotting)
 - BIAcore
 - Time-resolved FRET (TR-FRET)
 - Fluorescence polarization (FP)
- These bacterial targets are:
 - essential
 - attractive targets for antibiotic discovery

Yeast Two-Hybrid Analysis

Dnal interacts with 77ORF104

Dnal in activating domain;
77ORF104 in binding domain

Dnal in binding domain;
77ORF104 in activating domain


SD-TL

SD-THAL

SD-TL

SD-THAL

Dnal and
77ORF104



Dnal and
LamC



77ORF104
and LargeT



Dnal and
77ORF104




Dnal and
Large T



77ORF104
and LamC



Confirmation of 77ORF104/Dnal Interaction by BIAcore



Essentiality Analysis of *S. aureus* Target Genes

Gene inactivation/ replacement



Growth:
target
not essential

No growth:
suggests
target essentiality

Regulated gene expression



Growth
without inducer:
target
not essential

Growth only
with inducer:
suggests
target essentiality

DnaI Is an Essential *S. aureus* Gene

Gene inactivation/ replacement

No viable clones obtained.
Indication of gene essentiality.

DnaI pind. clone 1


DnaI pind. clone 2

RN4220


Regulated gene expression

+ inducer

- inducer




DnaI Involved in DNA Replication Initiation



77ORF104 Inhibits ³H-thymidine Incorporation

Effect of expression of 77ORF104 on synthesis of macromolecules



Representatives of Small Molecules with Antibacterial Activity against *S. aureus*

Small molecule	77ORF104-DnaI interaction IC ₅₀ (μM)	MIC (μg/mL)	DNA synthesis IC ₅₀ (μg/mL)
PT10056053	3	0.5 – 2	1
PT10023719	8	8 – 16	20
PT12008187	0.4	0.125 – 0.25	2

S. aureus DNA Replication Proteins Identified by Phage Inhibitory ORFs

Representative of inhibitory ORF family ^a	ORF size (aa)	Bacterial target identified	Function of target	Essentiality of target ^b
77ORF104 ORF016	52 297	DnaI	Helicase loader	Essential
ORF025 ORF168 ORF240	58 74 58	DnaN	DNA Pol III β subunit	Essential
ORF078	71	DnaG	DNA Primase	Essential
ORF140	101	PT-R14	Involved in DNA replication	Not determined

Summary

- PhageTech has sequenced the genomes of 46 phages of *S. aureus*, *S. pneumoniae*, and *P. aeruginosa*
- ? families of phage-derived antimicrobial ORFs were identified
- Several novel, essential bacterial targets, including *S. aureus* DnaI, have been discovered and patented
- Proprietary ORF-target binding assays and enzymatic assays have been developed around these targets
- Diverse libraries of small molecules are being screened for inhibitors
- Key advantages of the PhageTech drug discovery platform include:
 - **speed of analysis** of small phage genomes
 - access to **diversified targets**
 - **inherent validation** of the bacterial target
 - requisite **positive control** for target-based screening assays

Acknowledgements

Francis Arhin, Pascale Bauda, Dominique Bergeron, Mario Callejo, Mohammed Dehbi, Vincent Ferretti, Nhuan Ha, Tony Kwan, John McCarty, Greg Moeck, Ramakrishnan Srikumar, Dan Williams, Jinzi Wu and all technicians

Michael DuBow, Philippe Gros and Jerry Pelletier